Efficacy and safety of once-weekly semaglutide 1.0 mg vs once-daily liraglutide 1.2 mg as add-on to 1-3 oral antidiabetic drugs in subjects with type 2 diabetes (SUSTAIN 10).
Fiche publication
Date publication
septembre 2019
Journal
Diabetes & metabolism
Auteurs
Membres identifiés du Cancéropôle Est :
Pr VERGES Bruno
Tous les auteurs :
Capehorn MS, Catarig AM, Furberg JK, Janez A, Price HC, Tadayon S, Vergès B, Marre M
Lien Pubmed
Résumé
- SUSTAIN 10 compared the efficacy and safety of the anticipated most frequent semaglutide dose (1.0 mg) with the current most frequently prescribed liraglutide dose in Europe (1.2 mg), reflecting clinical practice.
Mots clés
Glucagon-like peptide-1 receptor agonist, Glycaemic control, Liraglutide, SUSTAIN, Semaglutide, Type 2 diabetes
Référence
Diabetes Metab.. 2019 Sep 10;: